Chimeric Polyamide Compounds for Fragile X Gene Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fragile X syndrome, fragile XE syndrome, and fragile X-associated tremor/ataxia syndrome (FXTAS) are inadequate in addressing the underlying genetic issues, particularly the reduced expression of the fmr1 and fmr2 genes and the overexpression of fmr1 mRNA.
Innovation Solution
Development of chimeric heterocyclic polyamide compounds that contain a recruiting moiety to bind to regulatory molecules and a DNA binding moiety to selectively target the CGG trinucleotide repeat sequences in the fmr1 and fmr2 genes, thereby modulating gene expression and correcting the defective gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for fragile X syndromes and FXTAS, then symptom management is provided, but the underlying genetic issues (reduced gene expression and overexpression of mRNA) are not addressed
Solution Approach 1:
The patent uses chimeric heterocyclic polyamide compounds as intermediary molecules that bridge the gap between conventional treatments and genetic correction. These compounds specifically bind to CGG repeat sequences in fmr1 and fmr2 genes, recruiting regulatory molecules to modulate gene expression and address the root cause of the diseases rather than just managing symptoms
Solution Approach 2:
The patent replaces conventional symptomatic treatment mechanisms with a molecular-level mechanism that directly interacts with genetic material. The chimeric polyamide compounds substitute traditional pharmacological approaches by using sequence-specific DNA binding and recruitment of regulatory molecules to correct gene expression defects at the molecular level
2Reliability
If the fmr1 gene has expanded CGG repeats, then the gene transcription is diminished and FMRP production is reduced, but the gene structure itself cannot be naturally corrected
Solution Approach 1:
The chimeric polyamide compounds act as intermediary agents that bind to the expanded CGG repeats and recruit regulatory molecules to restore normal transcription levels. This intermediary approach allows correction of the gene expression defect without requiring natural correction mechanisms that do not exist
Solution Approach 2:
The patent changes the parameter of gene transcription by introducing exogenous chimeric polyamide compounds that bind to the CGG repeats and alter the transcriptional state. This external intervention modifies the expression parameter without changing the underlying DNA sequence, achieving correction through parameter modulation rather than genetic editing
3Reliability
If the fmr2 gene has expanded CGG repeats, then the AFF2 protein expression is silenced, but conventional treatments cannot restore expression
Solution Approach 1:
The chimeric polyamide compounds serve as intermediary molecules that specifically target the silenced fmr2 gene by binding to its CGG repeats and recruiting regulatory molecules to restore AFF2 protein expression. This provides a new treatment option for gene silencing that was previously unavailable
Solution Approach 2:
The chimeric polyamide compounds demonstrate universality by being able to treat both fmr1 and fmr2 gene defects with the same mechanism. The compounds can address different genetic causes (fmr1 mutations and fmr2 mutations) that lead to different fragile X syndromes, providing a unified treatment approach for multiple conditions
4Reliability
If there are high CGG repeat counts in the 5' UTR region of fmr1, then excess mRNA is produced causing FXTAS, but the overexpression cannot be controlled by conventional means
Solution Approach 1:
The chimeric polyamide compounds act as intermediary regulators that bind to the 5' UTR region with high CGG repeats and recruit regulatory molecules to control mRNA transcription levels. This provides a mechanism to regulate otherwise uncontrolled transcription in FXTAS
Solution Approach 2:
The patent introduces a feedback mechanism where chimeric polyamide compounds bind to the fmr1 gene and recruit regulatory molecules that modulate transcription based on the presence of expanded CGG repeats. This creates a regulatory loop that can sense and respond to the abnormal repeat expansion, controlling mRNA levels dynamically
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed solution effectively increases the expression of the target genes, reducing the severity and frequency of symptoms associated with fragile X syndromes and FXTAS, and provides a promising treatment approach for these genetic disorders.
Implementation Method 1
compounds that contain a recruiting moiety to bind to regulatory molecules and a DNA binding moiety to selectively target the CGG trinucleotide repeat sequences
Data Source
AI summary
The present disclosure relates to compounds and methods which may be useful for modulating the expression of a target gene comprising a CGG trinucleotide repeat sequence and treating diseases and conditions in which the target gene plays an active role. The present disclosure provides compounds and methods for modulating the expression of fmr1 and fmr2, and provides compounds and methods for treating fragile X syndrome and fragile XE syndrome.